

Bipolar Depression – Pipeline Insight, 2020

<https://marketpublishers.com/r/B4A3D71C695CEN.html>

Date: September 2020

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: B4A3D71C695CEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Bipolar Depression – Pipeline Insight, 2020," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bipolar Depression Understanding

Bipolar Depression: Overview

Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).

Symptoms

During the manic phase, symptoms can include:

High level of energy and activity

Irritable mood

Decreased need for sleep

Exaggerated, puffed-up self-esteem ('grandiosity')

Rapid or 'pressured' speech

Rapid thoughts

Tendency to be easily distracted

Increased recklessness

False beliefs (delusions) or false perceptions (hallucinations)

Diagnosis

Since there are no medical tests to establish this diagnosis, a mental health professional diagnoses bipolar disorder based on a person's history and symptoms. The diagnosis is based not just on the current symptoms, but also take into account the problems and symptoms that have occurred through a person's life.

Treatment

A combination of medication and talk therapy is most helpful. Often more than one medication is needed to keep the symptoms in check.

Mood Stabilizers: The best-known and oldest mood stabilizer is lithium carbonate, which can reduce the symptoms of mania and prevent them from returning.

Antipsychotic Medications: In recent years, studies have shown that some of the newer antipsychotic medications can be effective for controlling bipolar disorder symptoms. Side effects often have to be balanced against the helpful effects of these drugs:

Olanzapine: sleepiness, dry mouth, dizziness and weight gain.

Risperidone: sleepiness, restlessness and nausea.

Quetiapine: dry mouth, sleepiness, weight gain and dizziness.

Ziprasidone: sleepiness, dizziness, restlessness, nausea and tremor.

Aripiprazole: nausea, stomach upset, sleepiness (or sleeplessness) or restlessness.

Asenapine: sleepiness, restlessness, tremor, stiffness, dizziness, mouth or tongue numbness.

Bipolar Depression Emerging Drugs Chapters

This segment of the Bipolar Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bipolar Depression Emerging Drugs

Lumateperone: Intra-Cellular Therapies

Lumateperone is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia, and currently in development for bipolar depression and other neurological indications. The most common side effects include sleepiness and dry mouth.

Zuranolone: SAGE Therapeutics

Zuranolone is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor.

Further product details are provided in the report

Bipolar Depression: Therapeutic Assessment

This segment of the report provides insights about the different Bipolar Depression drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bipolar Depression

There are approx. 20+ key companies which are developing the therapies for Bipolar Depression. The companies which have their Bipolar Depression drug candidates in the most advanced stage, i.e. phase III include, SAGE Therapeutics.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Depression drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve Bipolar Depression.

In July 2019, Intra-Cellular Therapies announced top-line results from two Phase 3 clinical trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p

Contents

- Introduction
- Executive Summary
- Bipolar Depression: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Bipolar Depression – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Bipolar Depression companies’ collaborations, Licensing, Acquisition -Deal Value
- Trends
- Bipolar Depression Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- NRX100: NeuroRx
 - Product Description
 - Research and Development
 - Product Development Activities
- Mid Stage Products (Phase II)
 - Comparative Analysis
- SEP 4199: Sunovion Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Zuranolone: SAGE Therapeutics

- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- SKL PSY: SK biopharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis
- Drug Name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
 - Comparative Analysis
- Bipolar Depression Key Companies
- Bipolar Depression Key Products
- Bipolar Depression- Unmet Needs
- Bipolar Depression- Market Drivers and Barriers
- Bipolar Depression- Future Perspectives and Conclusion
- Bipolar Depression Analyst Views
- Bipolar Depression Key Companies
- Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Bipolar Depression

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Bipolar Depression
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Bipolar Depression – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/B4A3D71C695CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B4A3D71C695CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970